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Linezolid for multidrug-
resistant tuberculosis
In their Comment in The Lancet 
Infectious Diseases, Kwok-Chiu Chang 
and colleagues
1 concluded that 
expansion of access to linezolid for 
complicated cases of drug-resistant 
tuberculosis risks the loss of a 
potentially useful drug and could 
promote the emergence and spread 
of drug-resistant tuberculosis in the 
community. The rationale behind 
this idea seems to be the scarcity 
of controlled clinical trials and, in 
particular, data for optimum linezolid 
dose. Although we agree that the 
evidence base is small, our recent 
systematic review
2 suggests that 
good outcomes can be achieved 
with linezolid among patients who 
would otherwise have very poor 
outcomes and high mortality. Among 
148 patients treated with linezolid, 
the rate of treatment success (68%) 
was at least as good as that expected 
for multidrug-resistant tuberculosis 
treatment overall (62%).
2,3 None of 
the authors of the studies included in 
that review advocates large-scale and 
indiscriminate use of linezolid for drug-
resistant tuberculosis. Conversely, in 
view of the poor side-eﬀ  ect  proﬁ  le 
and treatment complexity, linezolid is 
recommended for patients with few 
remaining treatment options, treated 
in well functioning programmes. 
The risk of emerging drug resistance 
is relevant, but no more so than for 
other second-line drugs presently 
used for drug-resistant tuberculosis. 
Existing treatment regimens are 
lengthy, are associated with sub  stantial 
side-eﬀ  ects, and result in overall poor 
outcomes. Unfortunately, controlled 
trials to deﬁ   ne better regimens are 
scarce. However, failure to scale up 
treatment access will lead to continued 
community transmission and 
worsening of the epidemic.
4 
Newer derivatives of linezolid with 
improved side-eﬀ  ect proﬁ  les are under 
development.
5 Meanwhile, linezolid 
should be available for patients with 
few treatment options, owing to either 
extensive drug resistance or previous 
treatment failure. We have started ﬁ  ve 
patients on strengthened linezolid and 
clofazimine-containing regimens in 
Khayelitsha, South Africa, all of whom 
produced negative sputum cultures 
within 3 months. Subsequent linezolid 
withdrawal was necessary in one 
patient because of severe peripheral 
neuropathy. Although side-eﬀ  ects 
need to be monitored and managed 
carefully, the restricting factor in the 
use of linezolid in our setting, where 
Pﬁ   zer holds a patent, is cost, rather 
than scarcity of evidence. In South 
Africa, linezolid is available in the public 
sector at a cost of US$1000 per patient 
per month.
Although improved access to 
linezolid alone will not solve the 
worldwide drug-resistant tuberculosis 
crisis, facilitation of access to new 
and repurposed drugs for drug-
resistant tuberculosis will contribute 
to the overall goal of a shorter, 
more tolerable, and more eﬀ  ective 
treatment regimen than is available at 
present, and will oﬀ  er the hope of cure 
to patients who would otherwise die.
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Authors’ reply
In our recent Comment,
1 we 
concluded that a “non-expensive 
and non-proprietary source 
of linezolid is insufficient to 
tackle the evolving global crisis 
of drug-resistant tuberculosis”. 
This conclusion was not simply 
based on “scarcity of controlled 
clinical trials and, in particular, 
data for optimum linezolid dose”, 
as suggested by Helen Cox and 
colleagues. Rather, the rationale was 
the difficult lessons that mankind 
has learned since anti-tuberculosis 
chemotherapy became available, 
especially in view of the wide social 
divide between rich and poor 
people, both within and between 
countries. We added a note of 
caution against the “introduction 
of linezolid on a large scale 
without careful planning or a well-
functioning health infrastructure”,
1 
which was reiterated by Cox and 
colleagues when they also suggested 
that “in view of the poor side-effect 
profile and treatment complexity, 
linezolid is recommended for 
patients with few remaining 
treatment options, treated in well 
functioning programmes”.
 
For people who are unaware 
of the problems in translation of 
anecdotal treatment efficacy into an 
actual public health effect, and the 
crucial need to promote treatment 
adherence by direct observation,
2 
the description of successful 
outcomes after unsupervised 
use of inexpensive linezolid in a 
case series of 29 patients with 
multidrug-resistant tuberculosis 
could inadvertently encourage 
indis  criminate use of the drug.
3 
Although the high cost of linezolid 
might have hindered its proper 
use, this factor has probably also 
reduced its indiscriminate use 
outside the programme setting. 
Whereas a pooled proportion of 
treatment success of 68% among 
patients with multidrug-resistant 
tuberculosis treated with linezolid Correspondence
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is at least as good as the expected 
success rate of 62%,
4 this figur  e 
still falls substantially short of 
treatment success rates reported for 
drug-susceptible tuberculosis. This 
fact emphasises the need for other 
essential elements to achieve fully 
effective disease control.  
To tackle drug-resistant tuber-
culosis, we need large-scale 
imple  mentation of an eﬀ  ective 
tuberculosis control programme 
built on the directly observed 
treatment short-course strategy, 
supported by proper regulation 
of high-quality  drug supply and a 
well funded health infrastructure, 
including funda  mental laboratory 
diagnostic services. Although 
linezolid might be the most 
promising repurposed agent in the 
treatment of complicated multi-
drug-resistant tuberculosis, its 
indiscriminate or unsupervised use 
still creates a major risk of treatment 
failure and further ampliﬁ   cation of 
drug resistance. Since several new 
drugs are now at an advanced stage 
of development, assessment of their 
clinical roles alongside linezolid in 
controlled clinical trials in a well 
functioning programme could be 
valuable.
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Daclatasvir: a promising 
triple therapy for 
children with chronic 
hepatitis C
We read with great interest the Article 
by Stanislas Pol and colleagues
1 on 
the use of daclatasvir in previously 
untreated adult patients with chronic 
hepatitis C genotype 1 infection.
Daclatasvir belongs to a class of 
new directly acting antivirals that 
inhibit non-structural protein NS5A, 
inhibiting hepatitis C virus RNA 
replication. Daclatasvir has inhibitory 
activity against hepatitis C virus, 
with broad genotypic coverage and a 
pharmacokinetic proﬁ  le that supports 
once-daily dosing.
2,3
Emerging drug-resistant hepatitis C 
virus variants have been reported 
previously in patients given daclatasvir 
in phase 1 monotherapy studies.
3 
However, as Pol and colleagues showed,
1 
an appropriate dose of daclatasvir, 
combined with peginterferon alfa-2a 
and ribavirin, suppresses resistant virus 
variants, and results in a more rapid and 
earlier decrease in plasma hepatitis C 
virus RNA than does dual peginterferon 
alfa-2a and ribavirin treatment. This 
randomised, multicentre, double-
blind, placebo-controlled phase 2a trial   
showed that patients given daclatasvir, 
mainly at a 10 mg or 60 mg dose, had 
a better extended rapid virological 
response at both 4 and 12 weeks of 
treatment, and a better sustained 
virological response at 24 months, 
than did those in the group given 
peginterferon alfa-2a plus ribavirin. 
Moreover, the investigators reported no 
diﬀ  erences in side-eﬀ  ects between the 
two treatment groups.
Although the treatment of 
children with chronic hepatitis C 
is controversial, daclatasvir’s good 
tolerability and the favourable eﬀ  ects 
of its combination with peginterferon 
alfa-2a plus ribavirin (triple therapy) 
encourage clinical trials in children, 
as suggested by the North American 
Society for Pediatric Gastroenter-
ology, Hepatology, and Nutrition 
(NASPGHAN).
4 Because no data exist 
for the toxicology of daclatasvir in 
children, a phase 1 clinical trial should 
be a prerequisite for a phase 2 trial; 
however, Pol and colleagues’ results 
support the possibility of a 
randomised, multicentre, blinded, 
placebo-controlled, dose-escalation 
phase 1–2 clinical trial being 
started. 48 children (age range 
6–17 years) with chronic hepatitis C 
genotype 1 infection and with the 
eligibility criteria re  commended by 
NASPGHAN
4 could be included in 
the trial. The patients should then 
be randomly assigned (1:1:1:1) into 
four groups, including 3 mg, 10 mg, 
and 30 mg doses of oral daclatasvir 
once daily, and a placebo. The 
recommended length of therapy is at 
least 48 months, and all 48 patients 
should receive once-weekly injections 
of 60 μg/m² peginterferon alfa-2a and 
15 mg/kg per day of oral ribavirin.
5 
As primary endpoints, this phase 1 
or 2 clinical trial should include both 
the identiﬁ  cation  of  side-eﬀ  ects 
associated with increasing doses 
and the eﬀ   ectiveness of daclatasvir 
that was measured by assessment of 
virological response during follow-up.
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